Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Execs: Veteran Developers Make Ideal Companion-Diagnostics Partners

This article was originally published in The Gray Sheet

Executive Summary

The market for drug-diagnostics pairings may still be evolving. But to develop these products, pharmaceutical companies know the partners they prefer: those with size and experience

You may also be interested in...



In Vitro Diagnostics: The Quest for Growth

The global economic downturn has put pressure on large, consumer-based in vitro diagnostic markets, such as diabetes glucose-testing, driving down sales, pricing, and profits. As a result, the IVD industry is actively seeking out higher growth opportunities to offset this impact-and it is finding solutions in several areas, branching into underserved emerging markets like China and India and targeting higher-growth clinical segments such as cancer, women's health, and infectious disease. But perhaps the biggest opportunity for future growth lies in the field of molecular diagnostics, particularly products that address the move toward more personalized care. Suppliers well positioned to take advantage of this opportunity are likely to experience strong growth ahead.

Bayer Places Consumer Cost Of Living Pressures 'Very High' On Agenda

Despite spiraling inflation, branded OTC product demand remains high, according to Bayer Consumer Health, which posted Q2 sales up by 16.0%. But with consumer incomes increasingly squeezed, the company is working on ways to defend its market share against cheaper private-label alternatives.

Over The Counter 8 Aug 2022: The ‘Dos and Don’ts’ Of EU Supplement Innovation, With Mihai Inceu

In this episode, HBW Insight talks to regulatory expert Mihai Inceu about the challenges of innovating in Europe’s thriving food supplements market. Senior regulatory affairs officer at consultancy firm Jensen R+, Inceu highlights some of the issues companies face in putting new wellness products onto the European market, particularly if they want to make health claims for herbal ingredients, also known as botanicals. As well as giving good advice about how to avoid getting into trouble with regulators, Inceu also points to some of the latest trends in this dynamic consumer health space.

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel